atypical hemolytic uremic syndrome ahus epidemiology forecast insight

DelveInsight’s ‘Atypical Hemolytic Uremic Syndrome (aHUS) - Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Atypical Hemolytic Uremic Syndrome (aHUS) Understanding

Atypical hemolytic uremic syndrome (aHUS) is a rare cause of thrombotic microangiopathy (TMA), characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, and multisystem end organ involvement, most commonly affecting the kidney.

 

Most cases of aHUS are genetic, although some may be acquired due to autoantibodies or occur for unknown reasons (idiopathic). aHUS may become chronic, and affected individuals may experience repeated episodes of the disorder. Unlike individuals with typical HUS, who usually recover from the life-threatening initial episode and usually respond well to supportive treatment, individuals with aHUS are much more likely to develop serious chronic complications such as severe high blood pressure (hypertension) and kidney (renal) failure.

 

aHUS is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow. It is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure.

 

Hemolytic Uremic Syndrome (HUS) is one of the disorders that belong to the spectrum of thrombotic microangiopathy (TMA). TMAs are a group of life-threatening diseases characterized by endothelial dysfunction and the presence of thrombi in small blood vessels. As the thrombus forms, there is the consumption of platelets and mechanical disruption of erythrocytes, which leads to thrombocytopenia and microangiopathic hemolytic anemia. Vessel occlusion results in tissue ischemia and organ damage, mainly affecting the kidneys, although other organs can be involved.

 

Atypical Hemolytic Uremic Syndrome (aHUS) Diagnosis

Diagnosing aHUS is complicated by the fact that it is more difficult to establish without a family history of the disorder. The diagnostic criteria associated with aHUS are hemolytic anemia (anemia in the presence of broken red blood cells), low platelet count (thrombocytopenia), and kidney dysfunction.

 

Most of the time, aHUS does not present with initial severe symptoms. The initial onset will most likely appear to be flu-like, with lethargic behavior, pale color, and a loss of appetite. It has been experienced that adult hospitals may often send the patient home with a flu diagnosis, while children’s hospitals may do a blood draw and conduct basic tests, such as Hemoglobin, Hematocrit, white blood cell counts, and platelet counts.

 

After initial blood tests, the hospital may conduct creatinine and BUN tests and may (or may not) reach an initial diagnosis of aHUS. The flu-like symptoms described above will continue to worsen when episodes are active. At this point, kidney function may begin to fall, often quite dramatically. Other organs sometimes experience problems in some cases. Quite often, seizures have been reported, along with other neurological issues. Sometimes gastronomical problems occur as well.

 

aHUS is a diagnosis of exclusion, ruling out (STEC) infection and other secondary causes of TMA , including (TTP). To exclude TTP, a blood test that measures the level of a protein called ADAMTS13 is used. The diagnostic tests for aHUS include blood tests (CBC and eGFR), specific test to differ from TTP, and genetic testing.

Epidemiology Perspective by DelveInsight

The Atypical Hemolytic Uremic Syndrome (aHUS) epidemiology division provides insights about historical and current aHUS patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

In the year 2020, the total prevalent cases of Atypical Hemolytic Uremic Syndrome was 7.0 thousand cases in the 7MM which are expected to grow during the study period, i.e., 2021-2034.

 

The disease epidemiology covered in the report provides historical as well as forecasted Atypical Hemolytic Uremic Syndrome epidemiology [segmented as Total Prevalent Cases of Atypical hemolytic uremic syndrome, Total Diagnosed Cases of Atypical hemolytic uremic syndrome, Total Age group-specific Cases of Atypical hemolytic uremic syndrome, and Total Treated Cases of Atypical hemolytic uremic syndrome] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country Wise- Atypical Hemolytic Uremic Syndrome (aHUS) Epidemiology

• Estimates show that the highest cases of Atypical Hemolytic Uremic Syndrome in the 7MM were in the United States, followed by Germany, France, Italy, Spain, the United Kingdom, and Japan in 2020.
• In the United States, the total number of prevalent cases of Atypical Hemolytic Uremic Syndrome was 3.5 thousand cases in the year 2020 which are expected to grow during the study period, i.e., 2021-2034.
• In the year 2020, the total prevalent cases of Atypical Hemolytic Uremic Syndrome were 3.1 thousand cases in EU-5 which are expected to grow during the study period, i.e., 2021-2034.
• In Japan, the total number of prevalent cases of Atypical Hemolytic Uremic Syndrome was 452 cases in the year 2020 which are expected to grow during the study period, i.e., 2021-2034.

Scope of the Report

• The Atypical Hemolytic Uremic Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The Atypical Hemolytic Uremic Syndrome Report and Model provide an overview of the risk factors and global trends of Atypical Hemolytic Uremic Syndrome in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of Atypical Hemolytic Uremic Syndrome in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Atypical Hemolytic Uremic Syndrome.
• The report provides the segmentation of the Atypical Hemolytic Uremic Syndrome epidemiology by total prevalent cases in the 7MM.
• The report provides the segmentation of the Atypical Hemolytic Uremic Syndrome epidemiology by total diagnosed cases in the 7MM.
• The report provides the segmentation of the Atypical Hemolytic Uremic Syndrome epidemiology by total age group-specific cases in the 7MM.
• The report provides the segmentation of the Atypical Hemolytic Uremic Syndrome epidemiology by total treated cases in the 7MM.

Report Highlights

• 10-Year Forecast of Atypical Hemolytic Uremic Syndrome epidemiology
• 7MM Coverage
• Total Prevalent Cases of Atypical Hemolytic Uremic Syndrome
• Total Diagnosed Cases of Atypical Hemolytic Uremic Syndrome
• Total Clinical Manifestation-Specific Cases of Atypical Hemolytic Uremic Syndrome
• Total Treated Cases (across lines) of Atypical Hemolytic Uremic Syndrome

KOL-Views

We interview KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM concerning the patient population of Atypical Hemolytic Uremic Syndrome?
• What are the key findings of the Atypical Hemolytic Uremic Syndrome epidemiology across the 7MM and which country will have the highest number of patients during the study period (2021-2034)?
• What would be the total number of patients of Atypical Hemolytic Uremic Syndrome across the 7MM during the study period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2021-2034)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2021-2034)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Atypical Hemolytic Uremic Syndrome?

Reasons to buy

The Atypical Hemolytic Uremic Syndrome Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Atypical Hemolytic Uremic Syndrome market
• Quantify patient populations in the global Atypical Hemolytic Uremic Syndrome market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Atypical Hemolytic Uremic Syndrome therapeutics in each of the markets covered
• Understand the magnitude of Atypical Hemolytic Uremic Syndrome population by its age group-specificity
• The Atypical Hemolytic Uremic Syndrome epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Atypical Hemolytic Uremic Syndrome Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population